At a glance
This program funds the next stage of previously Department of War-funded medical research and development that matches at least one FY26 JWMRP focus area. It supports late-stage preclinical work, late-stage technology development, technology demonstration, translational research, and, under a separate option, clinical research and clinical trials. Eligible applicants include DOW intramural and extramural organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities, but FFRDCs cannot receive awards directly. Applicants must have already received DOD/DOW core or Congressional Special Interest funding; awards go to organizations, not individuals. CDMRP expects about $8.8 million total, with roughly two awards capped at $1.4 million each and roughly two CRCTO awards capped at $3.0 million each; the maximum period of performance is 3 years, and cost sharing is not required unless an Other Transaction is used.
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. Projects must be relevant to at least one of the FY26 JWMRP focus areas. Distinctive Features: To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding. An MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO) is available to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/proposal materials.
Who can apply
- Unrestricted